Qosina's Pivot: From Component Supplier to MedTech Regulatory Strategist

RONKONKOMA, NY – August 18, 2026 – Qosina, a name synonymous with medical device components for nearly half a century, today announced a strategic move that signals a profound shift in the MedTech support ecosystem. With the launch of Qosina Regulatory Services, the company is expanding beyond its foundational business of supplying single-use parts to offer comprehensive regulatory and quality consulting. This pivot is not just an addition of a new service line; it's a calculated response to a market where the complexity of compliance has become as critical as the quality of a device's physical components.

For 45 years, Qosina built its reputation as an indispensable supplier, offering over 7,000 stock components that help medical device manufacturers accelerate product development. Now, it's betting that its future growth lies in helping those same customers navigate the increasingly treacherous waters of global regulation. The move positions Qosina to evolve from a transactional supplier into a deeply integrated strategic partner, a transformation that reflects broader economic and regulatory pressures shaping the entire healthcare industry.

The New Regulatory Gauntlet

The business case for Qosina's expansion is written in the fine print of global regulations. Medical device manufacturers, from nimble startups to established giants, are contending with a regulatory environment of unprecedented complexity. In the United States, the FDA's transition to the Quality Management System Regulation (QMSR), which harmonizes U.S. standards with the international ISO 13485:2016, has just come into force. This requires a fundamental shift in how companies manage quality, moving from legacy systems to risk-based processes that demand continuous monitoring and robust documentation.

This domestic shift is compounded by persistent challenges from the European Union's Medical Device Regulation (EU MDR) and In Vitro Diagnostic Regulation (IVDR), which demand extensive clinical evidence and post-market surveillance. The landscape is further complicated by the proliferation of AI/ML-enabled devices and Software as a Medical Device (SaMD), which are attracting intensified scrutiny from regulators. According to industry data, FDA Warning Letters for quality system violations surged by 58% in 2025, underscoring the heightened risk of non-compliance.

For a device manufacturer, a misstep in this labyrinthine environment is not a minor inconvenience; it can be an existential threat. Delays in market entry decimate revenue projections, while overlooked requirements, such as cybersecurity, can trigger costly redesigns or even force a product reclassification. It is this high-stakes reality that creates a fertile market for expert guidance.

A Strategic Shift From Parts to Partnership

Qosina's new venture aims to address these pain points by integrating regulatory strategy at the earliest stages of product development—often, at the point of component selection. The company is leveraging its existing relationships and deep-seated role in the supply chain to offer a more holistic solution. This is a classic strategy of moving up the value chain, capturing more revenue from an existing customer base while making its core business stickier.

"The regulatory issues that cost our customers the most time aren't the ones they saw coming," said Lee Pochter, CEO of Qosina, in the company's announcement. “A supplier change or a material substitution that seemed routine during development turns into a documentation problem much further down the road. Regulatory Services exist to catch that at the front end, so customers can make sourcing decisions with the right information in hand."

Pochter's statement cuts to the heart of the economic driver behind the move. By embedding regulatory foresight into the sourcing process, Qosina can save its clients from costly downstream errors, transforming a component purchase from a simple transaction into a strategic decision. This is particularly crucial for startups and small to medium-sized enterprises (SMEs), which often lack the in-house expertise and resources to manage the full spectrum of regulatory and quality requirements. By providing access to high-level consulting, Qosina is effectively democratizing regulatory expertise for the most innovative—and often most vulnerable—players in the market.

Crowded Field, Unique Proposition

Qosina is entering a competitive regulatory consulting arena populated by established specialists like Emergo by UL, NAMSA, and a host of other specialized firms. These companies offer deep expertise in navigating FDA submissions, CE-marking, and global quality systems. To succeed, Qosina must offer more than just another consulting hotline.

Its unique value proposition lies in the seamless integration of hardware and expertise. While a traditional consultant might advise on the requirements for a particular component, Qosina can provide the compliant component itself, complete with the necessary documentation and supply chain assurance. This one-stop-shop approach—spanning component sourcing, sampling, quality systems, submission work, and technical support—could significantly reduce friction and complexity for device manufacturers. The ability to consult on a design control and then immediately provide samples of compliant parts from an inventory of over 7,000 items is a powerful differentiator that standalone consulting firms cannot easily replicate.

Anchoring Expertise

To spearhead this ambitious initiative, the company has tapped Bryan Brosseau as its Regulatory and Quality Strategist. Brosseau is no newcomer; his profile signals a serious investment in credibility. With over 25 years in the medical device and biologics industries, he brings a wealth of experience in securing domestic and international approvals. His certifications as a lead auditor for ISO 13485, the Medical Device Single Audit Program (MDSAP), and EU MDR directly align with the most significant challenges facing the industry.

Brosseau's background in resolving FDA 483s and warning letters suggests a practical, problem-solving approach that will be essential for clients facing compliance crises. By placing a seasoned veteran at the helm, Qosina is making it clear that its new service is not a superficial add-on but a core strategic pillar built on deep industry knowledge.

As the MedTech industry continues to innovate at a breakneck pace, the regulatory frameworks that govern it will only become more complex. Qosina's strategic evolution is a clear indicator that in the modern medical device landscape, success depends not only on building a better product but on building a compliant one from the ground up.